Alkem Laboratories is looking at partnerships and in-licensing deals in the US to bolster its presence in the world's largest market for pharmaceutical products. It also remains positive about its growth prospects in the domestic market with better access to healthcare facilities and increasing penetration of medical insurance expected to act as key growth driver. In the medium to long term, the company's investment in the areas of control substances from its US facilities and biosimilars through its subsidiary at Enzene will also help drive growth.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
